HR3686-119

What This Bill Does

The SAFE Sunscreen Standards Act responds to the fact that no new sunscreen active ingredients have been approved through FDA's over-the-counter process since 1999 despite the 2014 Sunscreen Innovation Act. It amends Federal Food, Drug, and Cosmetic Act section 505G to require HHS/FDA to establish safety and efficacy standards for sunscreen active ingredients through guidance or regulation. Those standards must protect consumers using comprehensive scientific evidence, allow real-world evidence, observational studies, and other scientifically valid approaches instead of or in addition to traditional clinical tests, and apply the prima facie safe nonprescription marketing standard. FDA must consider nonclinical tests and alternatives to animal testing, and within 180 days issue guidance on how sponsors can use non-animal testing alternatives. The pending OTC sunscreen final administrative order must account for historical safe-use data for ingredients previously accepted in the United States, emphasize sunscreen as a skin-cancer prevention tool, and incorporate the new evidence and testing standards. HHS must report annually to House Energy and Commerce and Senate HELP on implementation, application reviews using the standards, and progress allowing nonclinical alternatives to animal testing, and must publish each report on FDA's website within seven days.

Who Benefits and How

Sunscreen ingredient sponsors benefit from clearer FDA standards that can use real-world evidence, observational studies, and non-animal testing. Consumers seeking sunscreen options benefit if more active ingredients can be reviewed without weakening safety standards. Skin cancer prevention advocates benefit because the bill treats sunscreen access as a prevention tool. Non-animal testing developers benefit from a statutory push for FDA guidance on alternative methods.

Who Bears the Burden and How

FDA OTC drug staff must write guidance or regulations, update the final administrative order, and report annually. HHS leadership must defend implementation progress to congressional health committees. Sunscreen sponsors must still produce comprehensive scientific evidence to demonstrate safety and effectiveness. Traditional animal-testing providers may see reduced demand if FDA accepts nonclinical alternatives.

Key Provisions

• Requires FDA standards for sunscreen active ingredient safety and efficacy.
• Allows real-world evidence, observational studies, and other scientifically valid approaches.
• Requires FDA to consider non-animal testing methods and issue guidance within 180 days.
• Updates the OTC sunscreen final administrative order to account for historical safe-use data.
• Requires annual public reports on implementation, reviewed applications, and nonclinical testing progress.